A Phase 2 interventional study of Within-Subject test of blinded study medication in Low Back Pain, Recurrent and Healthy, sponsored by Johns Hopkins University. Completed at 1 site in United States. Open to participants aged 18 Years to 60 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-21.
Sponsored by Johns Hopkins University · Phase 2, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 17 studies in Low Back Pain by Johns Hopkins University — 3 open to participants now, 3 under way, none of them phase 3. Low Back Pain · Johns Hopkins University.
Among the 17 studies in Low Back Pain by Johns Hopkins University, this one is the 9th largest by enrollment of the 16 interventional ones that give a count, is one of 2 that started in 2019, is one of 2 in phase 2, and was the 10th registered.
2,930 studies on the registry are indexed under Low Back Pain; 581 are open to participants now.
Browse Low Back Pain studies →3 of the 17 studies in Low Back Pain by Johns Hopkins University are open now, in 1 country. Recruiting first, the newest first:
Johns Hopkins University · Sites in United States
Ages 18–64
Johns Hopkins University · Sites in United States
Ages 18+
Johns Hopkins University · Sites in United States
Ages 18–64
By country, each count listing its studies:
Of the 332 Low Back Pain studies recruiting now, 93 (28%) set no upper age limit and 209 (63%) stop at 75 or younger; 8 take children under 18; 46 take healthy volunteers.
This study: 18 Years to 60 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
17 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 4 · Phase 3 1
First in 2005; this study’s year is marked. 2 started in 2019.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 109 is above the median of 60 across 2,369 interventional studies indexed under Low Back Pain.
Median enrollment 117 across the 16 interventional studies, 346 across the 1 observational. Of the 12 that completed or were terminated, 5 (42%) have results posted.
This tab as a report to print or save as PDF → With an account.
Johns Hopkins University is the lead sponsor of 1,817 studies on the registry; 316 are open to participants now.
Of its 208 completed or terminated interventional studies of FDA-regulated products, 144 (69%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 17 studies in Low Back Pain by Johns Hopkins University, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The central scientific premise of the proposed study is that sleep disruption (SD) will influence individuals' subjective response to blinded medication administration. The investigators further believe these responses will vary among patients who have chronic low back pain (CLBP) vs. healthy controls, and that sex will moderate effects.
The proposed study evaluates whether CLBP patients' subjective responses to study medication administration are altered by SD. The investigators focus on two outcome domains: abuse liability (i.e., drug liking and valuation) and response to pain testing.
The investigators propose a mixed between-within randomized crossover human-laboratory experiment that investigates placebo-controlled effects of study medication on 1) abuse liability metrics (Drug Liking and Monetary Valuation) and 2) response to laboratory-evoked standardized pain measures, after one night of uninterrupted sleep (US) and again after one night of SD. The investigators will recruit both CLBP patients(*) and healthy controls (N = 60).
(*) We originally aimed to accrue 60 subjects with CLBP. However, we have been granted approval by the National Institute on Drug Abuse (NIDA) to reduce expectations for the target N for the CLBP cohort. We are no longer expected to recruit N=60 CLBP participants; this is a COVID-19 modification, and we are not required to re-do a power analysis.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
General Inclusion Criteria:
CLBP-Specific Inclusion Criteria:
Exclusion Criteria:
General Exclusion Criteria:
Healthy Control and CLBP-Specific Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will be permitted to sleep without interruption for 8 hours.
Drug: Within-Subject test of blinded study medication
Participants will be repeatedly awakened throughout the night according to a standardized protocol.
Drug: Within-Subject test of blinded study medication
On the day after each sleep condition (Uninterrupted Sleep and Sleep Disruption), participants will undergo multiple injections of study medication or placebo. This is a double-blind within-subject Phase II trial. Participants receive up to four injections, starting with placebo (saline). This is followed by ascending doses of Hydromorphone (0.14, 0.28, and 0.56mg/70kg). This study uses a within-subject design, such that participants serve as participants' own control.
Drug Liking as Assessed by the Visual Analog Scale
Visual Analog Scale (0-100), where 0=None and 100 = Extremely , in response to the question, "Do you like the drug?" Values reported represent average values across time points in the drug administration assessment period (up to 420 minutes).
Time frame: up to 420 minute post-medication administration
Heat Pain Threshold
A thermode will gradually increase in temperature until the participant indicates when it "first feels painful". The outcome will be the temperature (degrees Celsius) at which the participant indicates they first feel pain. Values reported represent average values across time points in the drug administration assessment period (up to 420 minutes).
Time frame: up to 420 minute post-medication administration
Suprathreshold Tonic Heat Pain
A painful temperature above threshold will be held tonically for a period of time, after which pain ratings are obtained on a 0-100 numerical rating scale, where 0 = "No Pain" and 100 = "Worst Pain Imaginable." Values reported represent average values across time points in the drug administration assessment period (up to 420 minutes).
Time frame: up to 420 minute post-medication administration
Monetary Valuation of Drug as Assessed by the Drug vs. Money Multiple Choice Questionnaire
Participants are presented with an array of choices (in dollar value) which they will compare to the option of receiving study drug. They will decide for each choice whether they would take the money (at that value) or the drug they received in the session. The outcome will be the "crossover point", which is the mean of the last price that the participant selected "drug" and the first price at which the participant selected "money". Values reported represent those from a single administration following the drug administration assessment period.
Time frame: up to 420 minute post-medication administration
Good Drug Effects as Assessed by the Visual Analog Scale
Visual Analog Scale (0-100), where 0=None and 100 = Extremely , in response to the question, "Does the drug have any good effects?" Values reported represent average values across time points in the drug administration assessment period (up to 420 minutes).
Time frame: up to 420 minute post-medication administration
Bad Drug Effects as Assessed by the Visual Analog Scale
Visual Analog Scale (0-100), where 0=None and 100 = Extremely , in response to the question, "Does the drug have any bad effects?" Values reported represent average values across time points in the drug administration assessment period (up to 420 minutes).
Time frame: up to 420 minute post-medication administration
Level of "Highness" as Assessed by Visual Analog Scale
Visual Analog Scale (0-100), where 0=None and 100 = Extremely , in response to the question, "How high are you?" Values reported represent average values across time points in the drug administration assessment period (up to 420 minutes).
Time frame: up to 420 minute post-medication administration
Feeling of Sickness as Assessed by Visual Analog Scale
Visual Analog Scale (0-100), where 0=None and 100 = Extremely , in response to the question, "Does this drug make you feel sick?" Values reported represent average values across time points in the drug administration assessment period (up to 420 minutes).
Time frame: up to 420 minute post-medication administration
Clinical Pain
This will be rated on a 0-100 Numerical Rating Scale, where 0 = "No Pain" and 100 = "Worst Pain Imaginable." Values reported represent average values across time points in the drug administration assessment period (up to 420 minutes).
Time frame: up to 420 minute post-medication administration
Recruitment was conducted through print and media advertisements in the greater Baltimore metropolitan area, MyChart messages through the Johns Hopkins MyChart recruitment service, and contacting participants from previous laboratory studies who had previously agreed to be contacted for future studies. 109 participants were enrolled, 81 were ineligible and were not randomized. 28 participants were randomized.
| Milestone | Uninterrupted Sleep First, Then Sleep Disruption (CLBP) | Sleep Disruption First, Then Uninterrupted Sleep (CLBP) | Uninterrupted Sleep First, Then Sleep Disruption (Healthy Controls) | Sleep Disruption First, Then Uninterrupted Sleep (Healthy Controls) |
|---|---|---|---|---|
| Started | 2 | 3 | 12 | 11 |
| Placebo | 2 | 3 | 12 | 10 |
| Hydromorphone injections (0.14 mg) - 1 | 2 | 3 | 12 | 9 |
| Hydromorphone injections (0.28 mg) - 2 | 0 | 3 | 9 | 6 |
| Hydromorphone injections (0.56 mg/kg) - 3 | 0 | 1 | 0 | 1 |
| Completed | 2 | 3 | 12 | 10 |
| Not completed | 0 | 0 | 0 | 1 |
| Milestone | Uninterrupted Sleep First, Then Sleep Disruption (CLBP) | Sleep Disruption First, Then Uninterrupted Sleep (CLBP) | Uninterrupted Sleep First, Then Sleep Disruption (Healthy Controls) | Sleep Disruption First, Then Uninterrupted Sleep (Healthy Controls) |
|---|---|---|---|---|
| Started | 2 | 3 | 11 | 10 |
| Completed | 2 | 3 | 11 | 10 |
| Not completed | 0 | 0 | 0 | 0 |
| Milestone | Uninterrupted Sleep First, Then Sleep Disruption (CLBP) | Sleep Disruption First, Then Uninterrupted Sleep (CLBP) | Uninterrupted Sleep First, Then Sleep Disruption (Healthy Controls) | Sleep Disruption First, Then Uninterrupted Sleep (Healthy Controls) |
|---|---|---|---|---|
| Started | 2 | 3 | 11 | 8 |
| Placebo | 2 | 3 | 11 | 8 |
| Hydromorphone injections (0.14 mg) - 1 | 2 | 3 | 11 | 8 |
| Hydromorphone injections (0.28 mg) - 2 | 0 | 3 | 8 | 5 |
| Hydromorphone injections (0.56 mg/kg) - 3 | 0 | 1 | 0 | 1 |
| Completed | 2 | 3 | 11 | 8 |
| Not completed | 0 | 0 | 0 | 0 |
Visual Analog Scale (0-100), where 0=None and 100 = Extremely , in response to the question, "Do you like the drug?" Values reported represent average values across time points in the drug administration assessment period (up to 420 minutes).
| score on a scale | Uninterrupted Sleep/Healthy Control | Sleep Disruption/Healthy Control | Uninterrupted Sleep/CLBP | Sleep Disruption/CLBP |
|---|---|---|---|---|
| Drug Liking as Assessed by the Visual Analog Scale | 10.2 ± 20.5 | 5.6 ± 14.0 | 22.2 ± 29.1 | 16.4 ± 23.0 |
A thermode will gradually increase in temperature until the participant indicates when it "first feels painful". The outcome will be the temperature (degrees Celsius) at which the participant indicates they first feel pain. Values reported represent average values across time points in the drug administration assessment period (up to 420 minutes).
| degrees celsius | Uninterrupted Sleep/Healthy Controls | Sleep Disruption/Healthy Controls | Uninterrupted Sleep/CLBP | Sleep Disruption/CLBP |
|---|---|---|---|---|
| Heat Pain Threshold | 42.6 ± 3.2 | 41.7 ± 3.5 | 42.1 ± 2.8 | 41.4 ± 3.2 |
A painful temperature above threshold will be held tonically for a period of time, after which pain ratings are obtained on a 0-100 numerical rating scale, where 0 = "No Pain" and 100 = "Worst Pain Imaginable." Values reported represent average values across time points in the drug administration assessment period (up to 420 minutes).
| score on a scale | Uninterrupted Sleep/Healthy Controls | Sleep Disruption/Healthy Controls | Uninterrupted Sleep/CLBP | Sleep Disruption/CLBP |
|---|---|---|---|---|
| Suprathreshold Tonic Heat Pain | 46.0 ± 23.0 | 50.0 ± 26.0 | 60.0 ± 28.0 | 63.0 ± 29.0 |
Participants are presented with an array of choices (in dollar value) which they will compare to the option of receiving study drug. They will decide for each choice whether they would take the money (at that value) or the drug they received in the session. The outcome will be the "crossover point", which is the mean of the last price that the participant selected "drug" and the first price at which the participant selected "money". Values reported represent those from a single administration following the drug administration assessment period.
| US dollars | Uninterrupted Sleep/Healthy Controls | Sleep Disruption/Healthy Controls | Uninterrupted Sleep/CLBP | Sleep Disruption/CLBP |
|---|---|---|---|---|
| Monetary Valuation of Drug as Assessed by the Drug vs. Money Multiple Choice Questionnaire | 6.1 ± 7.1 | 3.4 ± 6.6 | 2.8 ± 4.9 | 8.5 ± 5.7 |
Visual Analog Scale (0-100), where 0=None and 100 = Extremely , in response to the question, "Does the drug have any good effects?" Values reported represent average values across time points in the drug administration assessment period (up to 420 minutes).
| score on a scale | Uninterrupted Sleep/Healthy Controls | Sleep Disruption/Healthy Controls | Uninterrupted Sleep/CLBP | Sleep Disruption/CLBP |
|---|---|---|---|---|
| Good Drug Effects as Assessed by the Visual Analog Scale | 8.4 ± 17.3 | 4.2 ± 11.0 | 20.5 ± 27.6 | 11.6 ± 21.0 |
Visual Analog Scale (0-100), where 0=None and 100 = Extremely , in response to the question, "Does the drug have any bad effects?" Values reported represent average values across time points in the drug administration assessment period (up to 420 minutes).
| score on a scale | Uninterrupted Sleep/Healthy Controls | Sleep Disruption/Healthy Controls | Uninterrupted Sleep/CLBP | Sleep Disruption/CLBP |
|---|---|---|---|---|
| Bad Drug Effects as Assessed by the Visual Analog Scale | 2.9 ± 8.4 | 8.4 ± 23.0 | 7.9 ± 16.1 | 7.9 ± 6.0 |
Visual Analog Scale (0-100), where 0=None and 100 = Extremely , in response to the question, "How high are you?" Values reported represent average values across time points in the drug administration assessment period (up to 420 minutes).
| score on a scale | Uninterrupted Sleep/Healthy Controls | Sleep Disruption/Healthy Controls | Uninterrupted Sleep/CLBP | Sleep Disruption/CLBP |
|---|---|---|---|---|
| Level of "Highness" as Assessed by Visual Analog Scale | 5.8 ± 10.9 | 7.4 ± 21.0 | 10.2 ± 17.6 | 4.9 ± 11.0 |
Visual Analog Scale (0-100), where 0=None and 100 = Extremely , in response to the question, "Does this drug make you feel sick?" Values reported represent average values across time points in the drug administration assessment period (up to 420 minutes).
| score on a scale | Uninterrupted Sleep/Healthy Controls | Sleep Disruption/Healthy Controls | Uninterrupted Sleep/CLBP | Sleep Disruption/CLBP |
|---|---|---|---|---|
| Feeling of Sickness as Assessed by Visual Analog Scale | 2.4 ± 8.4 | 7.1 ± 22.0 | 1.8 ± 6.5 | 4.7 ± 10.0 |
This will be rated on a 0-100 Numerical Rating Scale, where 0 = "No Pain" and 100 = "Worst Pain Imaginable." Values reported represent average values across time points in the drug administration assessment period (up to 420 minutes).
| score on a scale | Uninterrupted Sleep/Healthy Controls | Sleep Disruption/Healthy Controls | Uninterrupted Sleep/CLBP | Sleep Disruption/CLBP |
|---|---|---|---|---|
| Clinical Pain | 3.0 ± 7.7 | 1.1 ± 3.4 | 11.0 ± 15.0 | 18.0 ± 35.0 |
Collected over AEs were assessed at the Opioid challenge session (Visit 2), and again after each subsequent visit (Visit 3 and Visit 4), up to 9 days. This comprises all visits in which drug administration and/or sleep manipulations occurred.. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| (Healthy Controls): Uninterrupted Sleep | 0/28 (0%) | 0/28 (0%) | 3/28 (10.7%) |
| (Healthy Controls): Sleep Disruption | 0/28 (0%) | 0/28 (0%) | 2/28 (7.1%) |
| (CLBP): Uninterrupted Sleep | 0/28 (0%) | 0/28 (0%) | 1/28 (3.6%) |
| (CLBP):Sleep Disruption | 0/28 (0%) | 0/28 (0%) | 1/28 (3.6%) |
| Event | (Healthy Controls): Uninterrupted Sleep | (Healthy Controls): Sleep Disruption | (CLBP): Uninterrupted Sleep | (CLBP):Sleep Disruption |
|---|---|---|---|---|
| VomitingGastrointestinal disorders | 1/28 | 1/28 | 0/28 | 0/28 |
| Hip PainMusculoskeletal and connective tissue disorders | 1/28 | 0/28 | 0/28 | 0/28 |
| NauseaGastrointestinal disorders | 1/28 | 1/28 | 0/28 | 1/28 |
| ShinglesInfections and infestations | 0/28 | 0/28 | 1/28 | 0/28 |
| Age, Continuous(age in years) | Uninterrupted Sleep First, Then Sleep Disruption (CLBP) | Sleep Disruption First, Then Uninterrupted Sleep (CLBP) | Uninterrupted Sleep First, Then Sleep Disruption (Healthy Controls) | Sleep Disruption First, Then Uninterrupted Sleep (Healthy Controls) | Total |
|---|---|---|---|---|---|
| Mean | 32 ± 15 | 37 ± 10 | 40 ± 11 | 37 ± 11 | 37.82 ± 10.79 |
| Sex: Female, Male(Participants) | Uninterrupted Sleep First, Then Sleep Disruption (CLBP) | Sleep Disruption First, Then Uninterrupted Sleep (CLBP) | Uninterrupted Sleep First, Then Sleep Disruption (Healthy Controls) | Sleep Disruption First, Then Uninterrupted Sleep (Healthy Controls) | Total |
|---|---|---|---|---|---|
| Female | 1 | 1 | 8 | 8 | 18 |
| Male | 1 | 2 | 4 | 3 | 10 |
| Ethnicity (NIH/OMB)(Participants) | Uninterrupted Sleep First, Then Sleep Disruption (CLBP) | Sleep Disruption First, Then Uninterrupted Sleep (CLBP) | Uninterrupted Sleep First, Then Sleep Disruption (Healthy Controls) | Sleep Disruption First, Then Uninterrupted Sleep (Healthy Controls) | Total |
|---|---|---|---|---|---|
| Hispanic or Latino | 0 | 1 | 0 | 1 | 2 |
| Not Hispanic or Latino | 2 | 2 | 12 | 10 | 26 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Uninterrupted Sleep First, Then Sleep Disruption (CLBP) | Sleep Disruption First, Then Uninterrupted Sleep (CLBP) | Uninterrupted Sleep First, Then Sleep Disruption (Healthy Controls) | Sleep Disruption First, Then Uninterrupted Sleep (Healthy Controls) | Total |
|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 1 | 0 | 0 | 1 |
| Asian | 1 | 0 | 1 | 2 | 4 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 3 | 3 | 6 |
| White | 1 | 2 | 7 | 5 | 15 |
| More than one race | 0 | 0 | 1 | 0 | 1 |
| Unknown or Not Reported | 0 | 0 | 0 | 1 | 1 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Oct 2019 to primary completion in Apr 2025, 66 months.
Results were first posted in Oct 2026, 1 year 5 months after primary completion.
Of 33 phase 2 interventional studies under Low Back Pain, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 43. This study's 66 months is above that.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.